Cannabis-based medicines and medical cannabis for patients with neuropathic pain and other pain disorders: Nationwide register-based pharmacoepidemiologic comparison with propensity score matched controls.
Journal
European journal of pain (London, England)
ISSN: 1532-2149
Titre abrégé: Eur J Pain
Pays: England
ID NLM: 9801774
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
09
09
2021
received:
26
04
2021
accepted:
21
09
2021
pubmed:
9
10
2021
medline:
5
3
2022
entrez:
8
10
2021
Statut:
ppublish
Résumé
Neuropathic pain and other pain disorders have received attention as potential indications for use of cannabis-based medicines or medical cannabis (CBM/MC). Evidence regarding the efficacy and safety of CBM/MC for pain disorders is, however, insufficient. Denmark introduced a pilot programme of medical cannabis in January 2018. We aimed to evaluate efficacy, safety, and non-specific effects of CBM/MC used under the pilot programme compared with controls. We conducted a nationwide register-based cohort study in Denmark, identifying all individuals redeeming at least one prescription for CBM/MC for either neuropathic pain (n = 1817) or other and unspecified pain disorders (n = 924), and to match one control to each case using propensity score matching. Among both patient groups, users of THC used more opioids during follow-up than controls. Among patients with neuropathic pain, however, users of either CBD, THC, or combined CBD + THC used less gabapentin than controls. Users of all three classes of CBM/MC were hospitalized fewer days than controls among neuropathic-pain patients but not among patients with other or unspecified pain disorders. CBM/MC were generally safe and even displayed some positive effects among patients with neuropathic pain. We conclude that CBM/MC are safe and possibly efficacious for patients with neuropathic pain but not patients with other pain disorders. Patients with neuropathic pain may benefit from treatment with cannabis-based medicines or medical cannabis (CBM/MC), particularly in terms of reduced use of gabapentin and fewer days admitted to hospitals, compared with propensity score matched controls. CBM/MC did not, however, reduce the use of opioids. We did not find evidence that CBM/MC were effective for patients with other pain disorders.
Sections du résumé
BACKGROUND
Neuropathic pain and other pain disorders have received attention as potential indications for use of cannabis-based medicines or medical cannabis (CBM/MC). Evidence regarding the efficacy and safety of CBM/MC for pain disorders is, however, insufficient. Denmark introduced a pilot programme of medical cannabis in January 2018. We aimed to evaluate efficacy, safety, and non-specific effects of CBM/MC used under the pilot programme compared with controls.
METHODS
We conducted a nationwide register-based cohort study in Denmark, identifying all individuals redeeming at least one prescription for CBM/MC for either neuropathic pain (n = 1817) or other and unspecified pain disorders (n = 924), and to match one control to each case using propensity score matching.
RESULTS
Among both patient groups, users of THC used more opioids during follow-up than controls. Among patients with neuropathic pain, however, users of either CBD, THC, or combined CBD + THC used less gabapentin than controls. Users of all three classes of CBM/MC were hospitalized fewer days than controls among neuropathic-pain patients but not among patients with other or unspecified pain disorders.
CONCLUSIONS
CBM/MC were generally safe and even displayed some positive effects among patients with neuropathic pain. We conclude that CBM/MC are safe and possibly efficacious for patients with neuropathic pain but not patients with other pain disorders.
SIGNIFICANCE
Patients with neuropathic pain may benefit from treatment with cannabis-based medicines or medical cannabis (CBM/MC), particularly in terms of reduced use of gabapentin and fewer days admitted to hospitals, compared with propensity score matched controls. CBM/MC did not, however, reduce the use of opioids. We did not find evidence that CBM/MC were effective for patients with other pain disorders.
Substances chimiques
Medical Marijuana
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
480-491Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 European Pain Federation - EFIC®.
Références
Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2020). Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants, 9(1), 21. https://doi.org/10.3390/antiox9010021
Austin, P. C. (2009). Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Statistics in Medicine, 28(25), 3083-3107. https://doi.org/10.1002/sim.3697
Austin, P. C. (2011). An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behavioral Research, 46(3), 399-424. https://doi.org/10.1080/00273171.2011.568786
Babson, K. A., Sottile, J., & Morabito, D. (2017). Cannabis, cannabinoids, and sleep: A review of the literature. Current Psychiatry Reports, 19(4), 23. https://doi.org/10.1007/s11920-017-0775-9
Blum, K. (2018). Promoting Precision Addiction Management (PAM) to combat the global opioid crisis. Biomedical Journal of Scientific and Technical Research, 2(2), 1. https://doi.org/10.26717/bjstr.2018.02.000738
Boehnke, K. F., Litinas, E., & Clauw, D. J. (2016). Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. Journal of Pain, 17(6), 739-744. https://doi.org/10.1016/j.jpain.2016.03.002
Caputi, T. L., & Humphreys, K. (2018). Medical Marijuana users are more likely to use prescription drugs medically and nonmedically. Journal of Addiction Medicine, 12(4), 295-299. https://doi.org/10.1097/adm.0000000000000405
Celentano, D. (2020). The worldwide opioid pandemic: Epidemiologic perspectives. Epidemiologic Reviews, 42(1), 1-3. https://doi.org/10.1093/epirev/mxaa012
De Vita, M. J., Moskal, D., Maisto, S. A., & Ansell, E. B. (2018). Association of cannabinoid administration with experimental pain in healthy adults: A systematic review and meta-analysis. JAMA Psychiatry, 75(11), 1118-1127. https://doi.org/10.1001/jamapsychiatry.2018.2503
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018). The endogenous cannabinoid system: A budding source of targets for treating inflammatory and neuropathic pain. Neuropsychopharmacology, 43(1), 52-79. https://doi.org/10.1038/npp.2017.204
Fitzcharles, M. A., & Eisenberg, E. (2018). Medical cannabis: A forward vision for the clinician. European Journal of Pain, 22(3), 485-491. https://doi.org/10.1002/ejp.1185
Kildemoes, H. W., Sørensen, H. T., & Hallas, J. (2011). The Danish national prescription registry. Scandinavian Journal of Public Health, 39(7), 38-41. https://doi.org/10.1177/1403494810394717
Lev-Ran, S., Roerecke, M., Le Foll, B., George, T. P., McKenzie, K., & Rehm, J. (2014). The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. Psychological Medicine, 44(4), 797-810. https://doi.org/10.1017/S0033291713001438
Lile, J. A., Wesley, M. J., Kelly, T. H., & Hays, L. R. (2016). Separate and combined effects of gabapentin and Δ9-tetrahydrocannabinol in humans discriminating Δ9-tetrahydrocannabinol. Behavioural Pharmacology, 27(2-3), 215-224. https://doi.org/10.1097/FBP.0000000000000187
Lucas, P., Boyd, S., Milloy, M.-J., & Walsh, Z. (2020). Cannabis significantly reduces the use of prescription opioids and improves quality of life in authorized patients: Results of a large prospective study. Pain Medicine, https://doi.org/10.1093/pm/pnaa396
Lynge, E., Sandegaard, J. L., & Rebolj, M. (2011). The Danish national patient register. Scandinavian Journal of Public Health, 39(7 Suppl), 30-33. https://doi.org/10.1177/1403494811401482
Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42(5), 1262-1269. https://doi.org/10.1093/schbul/sbw003
Mason, B. J., Crean, R., Goodell, V., Light, J. M., Quello, S., Shadan, F., Buffkins, K., Kyle, M., Adusumalli, M., Begovic, A., & Rao, S. (2012). A proof-of-concept randomized controlled study of gabapentin: Effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology, 37(7), 1689-1698. https://doi.org/10.1038/npp.2012.14
Mercadante, S. (2019). Opioid analgesics adverse effects: The other side of the coin. Current Pharmaceutical Design, 25(30), 3197-3202. https://doi.org/10.2174/1381612825666190717152226
Moore, T. H. M., Zammit, S., Lingford-Hughes, A., Barnes, T. R. E., Jones, P. B., Burke, M., & Lewis, G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet, 370, 319-328. https://doi.org/10.1016/S0140-6736(07)61162-3
Mors, O., Perto, G. P., & Mortensen, P. B. (2011). The Danish psychiatric central research register. Scandinavian Journal of Public Health, 39(7 Suppl), 54-57. https://doi.org/10.1177/1403494810395825
Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Hauser, W. (2018). Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews, 3, https://doi.org/10.1002/14651858.CD012182.pub2. Online.
Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009). Cannabinoids as novel anti-inflammatory drugs. Future Medicinal Chemistry, 1(7), 1333-1349. https://doi.org/10.4155/fmc.09.93
Nielsen, S., Sabioni, P., Trigo, J. M., Ware, M. A., Betz-Stablein, B. D., Murnion, B., Lintzeris, N., Khor, K. E., Farrell, M., Smith, A., & Le Foll, B. (2017). Opioid-sparing effect of cannabinoids: A systematic review and meta-analysis. Neuropsychopharmacology, 42(9), 1752-1765. https://doi.org/10.1038/npp.2017.51
Nielsen, S. M., Toftdahl, N. G., Nordentoft, M., Hjorthøj, C., & Hjorthoj, C. (2017). Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study. Psychological Medicine, 47(9), 1668-1677. https://doi.org/10.1017/S0033291717000162
Nugent, S. M., Morasco, B. J., O’Neil, M. E., Freeman, M., Low, A., Kondo, K., Elven, C., Zakher, B., Motu'apuaka, M., Paynter, R., & Kansagara, D. (2017). The effects of cannabis among adults with chronic pain and an overview of general harms. Annals of Internal Medicine, 167(5), 319-331. https://doi.org/10.7326/M17-0155
Pedersen, C. B. (2011). The Danish Civil Registration System. Scandinavian Journal of Public Health, 39(7 suppl), 22-25. https://doi.org/10.1177/1403494810387965
Sahl Andersen, J., De Fine Olivarius, N., & Krasnik, A. (2011). The Danish national health service register. Scandinavian Journal of Public Health, 39(7), 34-37. https://doi.org/10.1177/1403494810394718
Stockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R., Murnion, B., Farrell, M., Weier, M., & Degenhardt, L. (2018). Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain, 159(10), 1932-1954. https://doi.org/10.1097/j.pain.0000000000001293
Stuart, E. A., Lee, B. K., & Leacy, F. P. (2013). Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. Journal of Clinical Epidemiology, 66(8 SUPPL.8), S84-S90.e1. https://doi.org/10.1016/j.jclinepi.2013.01.013
Stupinski, J., Bible, L., Asmar, S., Chehab, M., Douglas, M., Ditillo, M., Gries, L., Khurrum, M., & Joseph, B. (2020). Impact of marijuana on venous thromboembolic events: Cannabinoids cause clots in trauma patients. Journal of Trauma and Acute Care Surgery, 89(1), 125-131. https://doi.org/10.1097/TA.0000000000002667
Tahamtan, A., Tavakoli-Yaraki, M., Rygiel, T. P., Mokhtari-Azad, T., & Salimi, V. (2016). Effects of cannabinoids and their receptors on viral infections. Journal of Medical Virology, 88(1), 1-12. https://doi.org/10.1002/jmv.24292
Vadivelu, N., Kai, A. M., Kodumudi, V., Sramcik, J., & Kaye, A. D. (2018). The opioid crisis: A comprehensive overview. Current Pain and Headache Reports, 22(3), 1-6. https://doi.org/10.1007/s11916-018-0670-z
Vakharia, R. M., Sodhi, N., Anis, H. K., Ehiorobo, J. O., Mont, M. A., & Roche, M. W. (2020). Patients who have cannabis use disorder have higher rates of venous thromboemboli, readmission rates, and costs following primary total knee arthroplasty. Journal of Arthroplasty, 35(4), 997-1002. https://doi.org/10.1016/j.arth.2019.11.035
van Niekerk, G., Mabin, T., & Engelbrecht, A. M. (2019). Anti-inflammatory mechanisms of cannabinoids: An immunometabolic perspective. Inflammopharmacology, 27(1), 39-46. https://doi.org/10.1007/s10787-018-00560-7
Volkow, N. D., & Collins, F. S. (2017). The role of science in addressing the opioid crisis. New England Journal of Medicine, 377(4), 391-394. https://doi.org/10.1056/NEJMsr1706626